Get the Stockscreener App
1.56
0.64%
-0.01
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics Inc. to Host Earnings Call - ACCESS Newswire
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 21.3% - Defense World
Innovations in Stem Cell Therapy Market: Transforming - openPR
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
5 Best Stem Cell Companies to Invest In (March 2025) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Adaptive Biotechnologies (NASDAQ:ADPT) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Comparison - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, - openPR
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting By Investing.com - Investing.com Australia
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com - Defense World
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Brainstorm Cell Therapeutics faces Nasdaq delisting By Investing.com - Investing.com Nigeria
Brainstorm Cell Therapeutics faces Nasdaq delisting - Investing.com
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - GuruFocus.com
StockNews.com Downgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Sell - Defense World
Mesenchymal Stem Cells Market Outlook 2024: Emerging Trends and Regulatory Shifts Shaping the Future - WICZ
Global Stem Cell Characterization and Analysis Tool Market Size - WICZ
Equities Analysts Offer Predictions for BCLI FY2024 Earnings - Defense World
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn in ALS - Smartkarma
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - MSN
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program - GuruFocus.com
BrainStorm Cell Therapeutics Announces Key Milestones and Strategic Plans for ALS Therapy NurOwn® - Tandav Media
BrainStorm Cell Advances NurOwn ALS Treatment with FDA Special Protocol Assessment and Manufacturing Deal - StockTitan
BrainStorm Issues 2024 Letter to Shareholders - PR Newswire
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update - The Eastern Progress Online
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 - The Eastern Progress Online
Amyotrophic Lateral Sclerosis (ALS) Market: Segmentation - openPR
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Kilgore News Herald
Autologous Cell Therapy Market Expected to Grow at Rapid Rates - openPR
BrainStorm secures patent for exosome technology By Investing.com - Investing.com Nigeria
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Lelezard
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):